Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Ultragenyx nets $129.3mm via IPO

Executive Summary

Orphan disease drug developer Ultragenyx Pharmaceutical Inc. netted $129.3mm in its initial public offering of 6.6mm common shares (including the overallotment) at $21 each. The company had proposed selling 4.8mm shares between $14 and $17 each.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
      • Antibodies
Deal Status
  • Final
Deal Type
  • Financing
    • IPO

Related Companies